Courtney Gentleman, an executive at Synchrony Financial (NYSE:SYF), executed the sale of 4,338 shares of common stock on March 2, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at $67.71 each, producing proceeds of $293,725. The transaction was carried out under a Rule 10b5-1 trading plan that Gentleman adopted on November 5, 2025.
The filing also indicates that Gentleman acquired 9,768 shares on March 1, 2026. Those shares were received as restricted stock units (RSUs) that will vest in three equal annual installments, each installment representing a contingent right to receive one share of Synchrony Financial common stock. The RSUs were recorded at a price of $69.11 per share, for a total reported value of $675,066.
On the same March 1 filing date, the company withheld 3,452 shares to satisfy tax liabilities connected to the vesting of a portion of those restricted stock units. The withheld shares were valued at $69.11 each, totaling $238,567.
After these actions, Gentleman directly owns 19,831 shares of Synchrony Financial common stock.
Context for the transaction: Synchrony shares were trading at $68.66 at the time of the reporting, reflecting a 17% decline year-to-date. Despite the pullback, the stock was noted as carrying a low price-to-earnings multiple of 7.47.
Separately, Synchrony reported fourth-quarter 2025 results that aligned with analysts' expectations on a per-share basis but fell short on revenue. The company posted net earnings of $751 million, or $2.04 per diluted share, matching consensus forecasts. Revenue for the period came in at $3.79 billion, versus anticipated revenue of $3.84 billion.
On the strategic front, Synchrony outlined partnerships intended to broaden adoption of its CareCredit patient financing product. The company is working with Weave to integrate CareCredit into healthcare platforms to streamline financing for patients and operational steps for providers. It also expanded a strategic relationship with Planet DDS to embed CareCredit across dental practice management systems, with an explicit aim of reaching more than 2,500 orthodontic practices.
In market coverage developments, Baird upgraded Synchrony Financial's rating from Neutral to Outperform, citing the stock's valuation and positive employment trends as supportive factors for the upgrade. Separately, analysis from InvestingPro cited Fair Value calculations that indicate the stock appears undervalued, and noted that additional research is available through a comprehensive Pro Research Report covering SYF and other U.S. equities.
These items - the insider transactions, the quarter that met EPS but missed revenue, partnership extensions for CareCredit, and the analyst upgrade - together frame the most recent public developments around Synchrony Financial and its stock.